×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CGEN – compugen ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CGEN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
05:29 am
cgen
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]
Medium
Report
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]
11/13
02:14 am
cgen
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... [Yahoo! Finance]
Low
Report
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... [Yahoo! Finance]
11/12
07:00 am
cgen
Compugen Reports Third Quarter 2024 Results
Medium
Report
Compugen Reports Third Quarter 2024 Results
11/11
07:00 am
cgen
Compugen to Participate in Stifel 2024 Healthcare Conference
Low
Report
Compugen to Participate in Stifel 2024 Healthcare Conference
11/5
09:00 am
cgen
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
Neutral
Report
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
10/29
07:00 am
cgen
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Neutral
Report
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/7
07:00 am
cgen
Compugen to Present New Clinical Data at SITC 2024
Low
Report
Compugen to Present New Clinical Data at SITC 2024
9/9
07:00 am
cgen
Compugen to Present at Single Cell Genomics 2024 Conference
Medium
Report
Compugen to Present at Single Cell Genomics 2024 Conference
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
07:00 am
cgen
compugen ltd. - ordinary shares
MISS
Report
-15.8%
compugen ltd. - ordinary shares
8/6/2024
07:00 am
cgen
compugen ltd. - ordinary shares
BEAT
Report
-4.4%
compugen ltd. - ordinary shares
5/20/2024
07:00 am
cgen
compugen ltd. - ordinary shares
BEAT
Report
-15.9%
compugen ltd. - ordinary shares
3/5/2024
07:00 am
cgen
compugen ltd. - ordinary shares
BEAT
Report
-17.5%
compugen ltd. - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/9
Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
15.7%
3/17 Medicxi Bolsters and Expands Team with Senior Industry Leaders 12.8%
3/9 Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study 12.1%
11/5 Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019 11.1%
4/14 Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting 10.6%
4/28 Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 9.7%
4/6 Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies 9.1%
4/17 Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%
4/10 Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 8.7%
2/20 Compugen Reports Fourth Quarter and Full Year 2019 Results 7.5%
3/17 Medicxi Bolsters and Expands Team with Senior Industry Leaders 12.8%
3/9 Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study 12.1%
11/5 Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019 11.1%
4/14 Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting 10.6%
4/28 Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 9.7%
4/6 Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies 9.1%
4/17 Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%
4/10 Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 8.7%
2/20 Compugen Reports Fourth Quarter and Full Year 2019 Results 7.5%
TOP News Decliners
3/11
Compugen Announces Commencement of Public Offering of Ordinary Shares
-28.1%
3/13 Form 6-K COMPUGEN LTD For: Mar 13 -12.4%
5/20 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.170 ActVsEst 0.030 - Beat -9.2%
11/6 Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe -9.0%
2/24 Form 20-F COMPUGEN LTD For: Dec 31 -8.0%
2/21 Compugen Ltd. (NASDAQ: CGEN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock, up previously from $10.00. -6.1%
4/23 Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020 -6.1%
8/5 Form F-3 COMPUGEN LTD -5.3%
10/7 Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
4/28 Compugen Ltd. (NASDAQ: CGEN) had its price target raised by analysts at SunTrust Banks, Inc. from $16.00 to $22.00. They now have a "buy" rating on the stock. -4.9%
3/13 Form 6-K COMPUGEN LTD For: Mar 13 -12.4%
5/20 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.170 ActVsEst 0.030 - Beat -9.2%
11/6 Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe -9.0%
2/24 Form 20-F COMPUGEN LTD For: Dec 31 -8.0%
2/21 Compugen Ltd. (NASDAQ: CGEN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock, up previously from $10.00. -6.1%
4/23 Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020 -6.1%
8/5 Form F-3 COMPUGEN LTD -5.3%
10/7 Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
4/28 Compugen Ltd. (NASDAQ: CGEN) had its price target raised by analysts at SunTrust Banks, Inc. from $16.00 to $22.00. They now have a "buy" rating on the stock. -4.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: